ascopubs.org

Infusional CHOP Chemotherapy (CVAD) With or Without Chemosensitizers Offers No Advantage Over Standard CHOP Therapy in the Treatment of Lymphoma: A Southwest Oncology Group Study

Results of Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue in 22 Patients With Refractory or Recurrent Primary CNS Lymphoma or Intraocular Lymphoma PURPOSE: Two phase II studies were ...
Nature

The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience

Forty patients with T-ALL/LL were enrolled with a median age of 38 years (19–78 years). Twenty-three patients (58%) had T-ALL and 17 (43%) had LL. The performance status was ⩽2 in 36/40 (90%) patients ...
MedPage Today

Peripheral IV Access for Chemo Better Than Central Lines in Testicular Cancer?

Patients with testicular cancer had fewer venous access-related complications and overall thrombotic events when first-line chemotherapy was delivered via peripheral intravenous access compared with ...
EurekAlert!

New study adds to evidence on best CVAD securement methodology

FERNDALE, Mich. -- A new study on securement for central vascular access devices (CVAD) suggests that subcutaneous anchor securement systems (SASS) are shown to be more effective at keeping central ...
Healio

Adding nelarabine to hyper-CVAD appears safe, effective in adults with T-ALL

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — The addition of nelarabine to a standard hyper-CVAD regimen demonstrated durable overall response ...